Search Results

You are looking at 1 - 10 of 784 items for :

  • "screening" x
Clear All
Full access

Douglas E. Wood, George A. Eapen, David S. Ettinger, Lifang Hou, David Jackman, Ella Kazerooni, Donald Klippenstein, Rudy P. Lackner, Lorriana Leard, Ann N. C. Leung, Pierre P. Massion, Bryan F. Meyers, Reginald F. Munden, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Michael Unger and Stephen C. Yang

-year survival rates for lung cancer are only approximately 15.6%, partly because most patients have advanced-stage lung cancer at initial diagnosis ( http://seer.cancer.gov/statfacts/html/lungb.html ). 5 These facts, combined with the success of screening in

Full access

Therese B. Bevers, Benjamin O. Anderson, Ermelinda Bonaccio, Sandra Buys, Mary B. Daly, Peter J. Dempsey, William B. Farrar, Irving Fleming, Judy E. Garber, Randall E. Harris, Alexandra S. Heerdt, Mark Helvie, John G. Huff, Nazanin Khakpour, Seema A. Khan, Helen Krontiras, Gary Lyman, Elizabeth Rafferty, Sara Shaw, Mary Lou Smith, Theodore N. Tsangaris, Cheryl Williams and Thomas Yankeelov

Breast Cancer Screening and Diagnosis Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is

Full access

Randall W. Burt, Jamie A. Cannon, Donald S. David, Dayna S. Early, James M. Ford, Francis M. Giardiello, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Kory Jasperson, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, David Weinberg, Mary Dwyer and Deborah Freedman-Cass

of -2.7% in men and -2.1% in women from 2004 to 2008. 3 In addition, mortality from CRC decreased by almost 35% from 1990 to 2007, 4 likely because of earlier diagnosis through screening and better treatment modalities. Currently, patients with

Full access

Edward E. Partridge, Nadeem R. Abu-Rustum, Susan M. Campos, Patrick J. Fahey, Michael Farmer, Rochelle L. Garcia, Anna Giuliano, Howard W. Jones III, Subodh M. Lele, Richard W. Lieberman, Stewart L. Massad, Mark A. Morgan, R. Kevin Reynolds, Helen E. Rhodes, Diljeet K. Singh, Karen Smith-McCune, Nelson Teng, Cornelia Liu Trimble, Fidel Valea and Sharon Wilczynski

women without access to health care and those who have immigrated to the United States from countries where cervical cancer screening is not routinely performed. 2 Because cervical cytology screening is the current method for early detection of this

Full access

Michael J. Hall

intensive screening. 1 Carriers may also elect to share personal genetic information with family members. For individuals at risk of having a familial mutation, confirmatory testing can diagnose or rule-out Lynch, allowing screening to be targeted

Full access

Constance D. Lehman and Robert A. Smith

for intensive mammographic surveillance were supported. Several organizations recommended annual mammography starting at 25 years of age for women identified at high risk. Eventually, it became clear that mammography was a poor method of screening

Full access

Douglas E. Wood, Ella A. Kazerooni, Scott L. Baum, George A. Eapen, David S. Ettinger, Lifang Hou, David M. Jackman, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Samir S. Makani, Pierre P. Massion, Peter Mazzone, Robert E. Merritt, Bryan F. Meyers, David E. Midthun, Sudhakar Pipavath, Christie Pratt, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Peter B. Sachs, Matthew B. Schabath, Mark L. Schiebler, Betty C. Tong, William D. Travis, Benjamin Wei, Stephen C. Yang, Kristina M. Gregory and Miranda Hughes

these symptoms usually have advanced lung cancer. These facts—combined with the success of cervical, colon, and breast cancer screening—have been the impetus for developing an effective lung cancer screening (LCS) test. 8 – 10 Ideally, effective

Full access

Alex J. Mitchell

P erhaps the most important development in psychooncology in the past 10 years has been the development and testing of short, user-friendly screening tools for distress. Attempts to validate these tools have helped crystallize the concept of

Full access

Therese B. Bevers, Mark Helvie, Ermelinda Bonaccio, Kristine E. Calhoun, Mary B. Daly, William B. Farrar, Judy E. Garber, Richard Gray, Caprice C. Greenberg, Rachel Greenup, Nora M. Hansen, Randall E. Harris, Alexandra S. Heerdt, Teresa Helsten, Linda Hodgkiss, Tamarya L. Hoyt, John G. Huff, Lisa Jacobs, Constance Dobbins Lehman, Barbara Monsees, Bethany L. Niell, Catherine C. Parker, Mark Pearlman, Liane Philpotts, Laura B. Shepardson, Mary Lou Smith, Matthew Stein, Lusine Tumyan, Cheryl Williams, Mary Anne Bergman and Rashmi Kumar

This decrease has been attributed to mammographic screening and treatment advances. 5 Diagnostic Evaluation Breast symptoms are common among women. A retrospective study of women aged 40 to 70 years showed that 16% (total visits of 23 per 100

Full access

Jennifer A. Lewis, Heidi Chen, Kathryn E. Weaver, Lucy B. Spalluto, Kim L. Sandler, Leora Horn, Robert S. Dittus, Pierre P. Massion, Christianne L. Roumie and Hilary A. Tindle

5-year survival of only 18%. 1 Low-dose CT (LDCT) can detect early-stage lung cancer, increasing the likelihood of cure. The National Lung Screening Trial (NLST), a large, multicenter, US randomized controlled trial, was terminated early when it